161 related articles for article (PubMed ID: 34468979)
1. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K
Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.
Collins J; van Noort M; Rathi C; Post TM; Struemper H; Jewell RC; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1411-1424. PubMed ID: 37465991
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
Iida S; Sunami K; Mishima Y; Fujii T; Kato H; Terao T; Matsuzawa Y; Matsubara M; Crossman T; Kremer BE; Gupta I
Int J Hematol; 2023 Nov; 118(5):596-608. PubMed ID: 37668832
[TBL] [Abstract][Full Text] [Related]
5. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
Cardellino A; Correll JR; Martin M; Gorsh B; Sapra S; Popat R
Front Oncol; 2023; 13():1274659. PubMed ID: 38144529
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.
Springer C; Krauter J; Trummer A
Oncotarget; 2023 Dec; 14():949-956. PubMed ID: 38039414
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Suvannasankha A; Bahlis N; Trudel S; Weisel K; Koenecke C; Oriol A; Voorhees PM; Alonso AA; Callander NS; Mateos MV; Reddy N; Hakim S; LaMacchia J; Patel N; Williams D; Jewell RC; Zhou X; Gupta I; Opalinska J; Nooka AK
Cancer; 2024 Apr; ():. PubMed ID: 38630908
[TBL] [Abstract][Full Text] [Related]
9. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.
Trudel S; McCurdy A; Louzada ML; Parkin S; White D; Chu MP; Kotb R; Mian H; Othman I; Su J; Khan A; Gul E; Reece D
Nat Med; 2024 Feb; 30(2):543-551. PubMed ID: 38177852
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).
Alegre A; Benzo G; Alonso R; Martínez-López J; Jimenez-Ubieto A; Cuéllar C; Askari E; Prieto E; Aláez C; Aguado B; Velasco A; Krsnik I; Bocanegra A; Llorente L; Muñoz-Linares C; Morales A; Giménez E; Iglesias R; Martínez-Chamorro C; Alonso A; Jiménez-Montes C; Blanchard MJ;
Oncol Ther; 2023 Mar; 11(1):83-96. PubMed ID: 36509945
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study.
Roussel M; Texier N; Nael V; Bitetti J; Paka P; Kerbouche N; Sail L; Colin X; Leleu X
Eur J Haematol; 2024 May; ():. PubMed ID: 38722078
[TBL] [Abstract][Full Text] [Related]
12. Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Khwaja J; Bomsztyk J; Atta M; Bygrave C; Forbes A; Durairaj S; Fernandes S; Taylor J; Paterson P; Brearton G; Crawley C; Sheehy O; Brown R; Soutar R; Garg M; Rydzewski A; Jamroziak K; Mahmood S; Wechalekar AD
Br J Haematol; 2024 May; 204(5):1811-1815. PubMed ID: 38171355
[TBL] [Abstract][Full Text] [Related]
13. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Dimopoulos MA; Beksac M; Pour L; Delimpasi S; Vorobyev V; Quach H; Spicka I; Radocha J; Robak P; Kim K; Cavo M; Suzuki K; Morris K; Pompilus F; Phillips-Jones A; Zhou XL; Fulci G; Sule N; Kremer BE; Opalinska J; Mateos MV; Trudel S;
N Engl J Med; 2024 Jun; ():. PubMed ID: 38828951
[TBL] [Abstract][Full Text] [Related]
14. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Ribas de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Aparecida Martinez G; Sureda Balarí AM; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah AO; Oriol A; Gatt ME; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; McKeown A; McNamara S; Zhou X; Nichols M; Lewis E; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos MV;
N Engl J Med; 2024 Jun; ():. PubMed ID: 38828933
[TBL] [Abstract][Full Text] [Related]
15. Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma.
Rodriguez-Otero P; Tamariz LE; San-Miguel JF
Lancet Haematol; 2023 Oct; 10(10):e786-e787. PubMed ID: 37793761
[No Abstract] [Full Text] [Related]
16. Semi-automation of keratopathy visual acuity grading of corneal events in belantamab mafodotin clinical trials: clinical decision support software.
Talekar MK; Painter JL; Elizalde MA; Thomas M; Stein HK
Front Digit Health; 2023; 5():1138453. PubMed ID: 37881364
[TBL] [Abstract][Full Text] [Related]
17. Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.
Singh RK; Jones RJ; Shirazi F; Qin L; Zou J; Hong S; Wang H; Lee HC; Patel KK; Wan J; Choudhary RK; Kuiatse I; Pahl A; Orlowski RZ
Res Sq; 2024 Jan; ():. PubMed ID: 38260385
[TBL] [Abstract][Full Text] [Related]
18. Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patients.
Avivi I; Shragai T; Luttwak E; Trestman S; Cohen YC
Eur J Haematol; 2024 Mar; 112(3):367-370. PubMed ID: 37882735
[TBL] [Abstract][Full Text] [Related]
19. Corneal epithelial changes in a patient treated with belantamab mafodotin.
Inferrera L; Giglio R; Tognetto D
Taiwan J Ophthalmol; 2023; 13(3):380-383. PubMed ID: 38089508
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
